The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
Open accessAbstract
OBJECTIVE—Hyperglycemia is a risk factor for microvascular complications and may increase the risk of cardiovascular disease in patients with type 2 diabetes. This study tested the LDL cholesterol–lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy. RESEARCH DESIGN AND METHODS—A 26-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study was carried out between August 2004 and August 2006 to evaluate the efficacy and safety of colesevelam for reducing A1C in adults with type 2 diabetes whose glycemic control was inadequate (A1C 7.5–9.5%) with existing sulfonylurea monotherapy or sulfonylurea in combination with additional oral antidiabetes agents. In total, 461 patients were randomized (230 given colesevelam 3.75 g/day and 231 given placebo). The primary efficacy measurement was mean placebo-corrected change in A1C from baseline to week 26 in the intent-to-treat population (last observation carried forward). RESULTS—The least squares (LS) mean change in A1C from baseline to week 26 was −0.32% in the colesevelam group and +0.23% in the placebo group, resulting in a treatment difference of −0.54% (P < 0.001). The LS mean percent change in LDL cholesterol from baseline to week 26 was −16.1% in the colesevelam group and +0.6% in the placebo group, resulting in a treatment difference of −16.7% (P < 0.001). Furthermore, significant reductions in fasting plasma glucose, fructosamine, total cholesterol, non–HDL cholesterol, and apolipoprotein B were demonstrated in the colesevelam relative to placebo group at week 26. CONCLUSIONS—Colesevelam improved glycemic control and reduced LDL cholesterol levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
Kannel, W. B., & McGee, D. L. (1979) · Diabetes Care · doi:10.2337/diacare.2.2.120 · Cited by 1,203 · cited 1×
“Although the impact of hyperglycemia on macrovascular complications is unknown, individuals with type 2 diabetes have a two- to fourfold higher risk for initial coronary events, and more importantly, those developing coronary heart disease have a relatively poor prognosis for recurrent coronary heart disease events an…”
BackgroundStandards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Cited by
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Self-citationUpdate on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591
“For example, administration of colesevelam, a high- capacity bile acid binding polymer, to humans with type 2 diabetes reduced not only cholesterol and low-density lipoprotein, as expected, but also decreased hemoglobin A1c (12,13).”
BackgroundInfluentialBile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Beyond intestinal soap—bile acids in metabolic control
Kuipers, F., Bloks, V. W., & Groen, A. K. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.60 · Cited by 454
The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation
Pols, T. W. H., Noriega, L. G., Nomura, M., Auwerx, J., & Schoonjans, K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.004 · Cited by 454
Bile Acids and Metabolic Regulation
Staels, B., & Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s355 · Cited by 415
Self-citationPournaras, D. J., Glicksman, C., Vincent, R. P., Kuganolipava, S., Alaghband-Zadeh, J., Mahon, D., Bekker, J. H. R., Ghatei, M. A., Bloom, S. R., Walters, J. R. F., et al. (2012) · Endocrinology · doi:10.1210/en.2011-2145 · Cited by 383
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 290
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Porez, G., Prawitt, J., Gross, B., & Staels, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024794 · Cited by 286
Role of the Gut Microbiome in Obesity and Diabetes Mellitus
Barlow, G. M., Yu, A., & Mathur, R. (2015) · Nutrition in Clinical Practice · doi:10.1177/0884533615609896 · Cited by 262
The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes
Alberto González-Regueiro, J., Moreno-Castañeda, L., Uribe, M., & Carlos Chávez-Tapia, N. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5494 · Cited by 247
Nakatani, H., Kasama, K., Oshiro, T., Watanabe, M., Hirose, H., & Itoh, H. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.006 · Cited by 192
Bile Acids, Obesity, and the Metabolic Syndrome
Ma, H., & Patti, M. E. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.004 · Cited by 176
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Self-citationRole of bile acids in the regulation of the metabolic pathways
Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., Tsubota, K., & Watanabe, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i13.260 · Cited by 80
Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review
Ooi, C. P., & Loke, S. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12295 · Cited by 39
Efficacy of colesevelam on lowering glycemia and lipids
Aggarwal, S., Loomba, R. S., & Arora, R. R. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31823a109f · Cited by 30
“Most common side effects reported with colesevelam are gastrointestinal: constipation, dyspepsia, and flatulence.(4,8,13,32,33) Colesevelam has been shown to be well tolerated by various populations.”
BackgroundRole of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Self-citationLickteig, A. J., Csanaky, I. L., Pratt-Hyatt, M., & Klaassen, C. D. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw054 · Cited by 26
Sedgeman, L. R., Beysen, C., Allen, R. M., Ramirez Solano, M. A., Turner, S. M., & Vickers, K. C. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00238.2018 · Cited by 22
Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus
Levy, P. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0087 · Cited by 15
Metadata
- Authors
- Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., & Jones, M. R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-08-01
- Volume
- 31
- Issue
- 8
- Pages
- 1479-1484
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2046189497
- Cited by
- 246
- References
- 8
- FWCI
- 19.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.